Description of the Business
Trellus Health is commercialising the provision of digital chronic condition management solutions for employers and health plans that utilise the scientifically validated GRITT™ resilience-based methodology and a proprietary HIPAA-compliant technology platform called TrellusElevate™ to coordinate and deliver care remotely via telemedicine. The Company is initially focused on Inflammatory Bowel Diseases (IBD), which include the chronic incurable conditions of Crohn’s Disease and ulcerative colitis, but considers its approach to have potential utility and demand across many chronic conditions.
The TrellusElevate™ platform is the Company’s proprietary connected health platform that incorporates the GRITT™ methodology and learnings on resilience from clinical research and practice conducted at the Mount Sinai IBD Center for more than five 5 years. The GRITT™ methodology and resilience-driven multidisciplinary care model have been scientifically validated to demonstrate meaningful improvements in patient outcomes and over 85 per cent. reduction in unplanned healthcare utilisation (emergency department visits and hospitalisations) which the Directors believe indicates the potential for significant cost savings for healthcare payers.
The Company was formed in July 2020 as a UK incorporated company, with the exclusive license for commercialisation of the GRITT™ technology for IBD and seven broad disease categories granted by the Icahn School of Medicine at Mount Sinai (ISMMS). On 20 August 2020, EKF Diagnostics Holdings plc (EKF) announced that it had led, in partnership with ISMMS, a $5 million strategic investment into the Company.